|
Powered by Cell Signaling Technology |
Site Information |
---|
GEVAPDAksFVLNLG SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 475607 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
References | |
---|---|
Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51
23954790 Curated Info |
|
Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773 Curated Info |
|
Moritz A (2010) CST Curation Set: 9919; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861 Curated Info |
|
Cherry J (2007) CST Curation Set: 2315; Year: 2007; Biosample/Treatment: cell line, Nomo-1/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2316; Year: 2007; Biosample/Treatment: cell line, Nomo-1/SAHA; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2317; Year: 2007; Biosample/Treatment: cell line, Nomo-1/SAHA; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2006) CST Curation Set: 2029; Year: 2006; Biosample1/Treatment/Isotope: cell line, MV4-11/SAHA/L, Biosample2/Treatment/Isotope: cell line, MV4-11/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2006) CST Curation Set: 2030; Year: 2006; Biosample1/Treatment/Isotope: cell line, MV4-11/SAHA/L, Biosample2/Treatment/Isotope: cell line, MV4-11/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2006) CST Curation Set: 2033; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2006) CST Curation Set: 2034; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2006) CST Curation Set: 2036; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2006) CST Curation Set: 1658; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |